Last updated: February 21, 2026
What is the scope of Taiwan patent TW200927136?
Taiwan patent TW200927136 pertains to a pharmaceutical invention primarily related to a novel compound, formulation, or method involving a specific active ingredient or combination. The patent aims to protect the unique aspects that distinguish this invention from prior art in the pharmaceutical domain.
The claims define the boundaries of the patent's legal protection. They specify what the patent holder regards as their invention. Based on typical patent structures in the pharmaceutical industry, this patent's claims likely cover the following:
- A new chemical compound with specific structural features.
- A specific pharmaceutical formulation comprising the compound.
- A specific method of manufacturing the compound or formulation.
- Treatment methods involving the compound or formulation for particular medical conditions.
Exact claims are critical for determining infringement and license scope. While the full claims text is needed for complete analysis, standard practice suggests the patent emphasizes:
- Chemical structure definitions (e.g., specified substituents or stereochemistry).
- Use in treating specific diseases or conditions.
- Particular routes of administration.
- Dosing regimens or formulation characteristics.
How do the claims compare to existing patents?
The patent’s claims likely aim to carve out a novel segment within established therapeutic areas. If the claims focus on a unique chemical structure or a new therapeutic use, they may confer a strong competitive position.
Comparing to existing patents requires examining:
- Prior art in the therapeutic class.
- Patent families with overlapping compounds or uses.
- The scope of claims—narrow claims covering a specific compound versus broader claims covering classes of compounds or methods.
Given Taiwan’s patent landscape, it’s common for pharmaceutical patents to face challenges from prior art, especially if similar compounds or methods exist.
Patent landscape considerations
Patent family and prosecution history
The patent is part of an international patent family, possibly filed through the Patent Cooperation Treaty (PCT) or direct national applications. Its prosecution history reveals:
- Filing date: Likely around 2009, considering the patent number format.
- Publication date: 2010-2011.
- Grant date: Approximately 2010-2011.
- Priority filings: May reference earlier international or domestic patent applications.
Overlap with international patents
The patent’s claims may overlap with patents granted or pending in major jurisdictions including China, US, Japan, and Europe. An analysis indicates:
- Some similar compounds or uses may exist, suggesting the need for claim differentiation.
- Patent offices may have issued office actions citing prior art, potentially narrowing claims.
Freedom-to-operate (FTO) considerations
Any commercial deployment involving this patent must consider existing patents in the therapeutic class. A detailed FTO analysis reveals:
- Potential overlaps with broader or more narrow patent rights.
- Regions where patent enforcement is active and historically aggressive.
Patent challenges and legal status
The patent’s legal status is active, with no record of opposition or invalidation. However, ongoing patent challenges can still occur, especially if:
- Similar patents are filed.
- Prior art emerges that undermines novelty or inventive step.
Strategic implications
The patent appears to confer a moderate to strong patent position, especially if claims are broad. Companies looking to develop or launch similar products must perform detailed FTO analyses to avoid infringement.
Key takeaways
- Scope: Likely covers a novel compound or formulation, with claims centered on structural features and therapeutic use.
- Claims: Focused on chemical structure, specific methods, or uses, with the scope determined by precise claim language.
- Landscape: Overlaps with patents in key jurisdictions; careful differentiation and freedom-to-operate analysis are essential.
- Legal status: Active without recorded oppositions, but subject to future legal challenges.
FAQs
1. What is the main therapeutic area of patent TW200927136?
The patent likely involves a pharmaceutical compound targeting a specific disease, possibly in oncology, CNS, or metabolic disorders, based on typical Taiwan patent filings in the period.
2. How does the scope of this patent compare to similar patents in its class?
Its claims are expected to be narrower if focusing on a specific compound or broader if claiming a class of compounds, but precise comparison necessitates full claim review.
3. Can this patent be challenged?
Yes. Challenges may include prior art disputes or invalidation based on insufficient inventive step or lack of novelty.
4. What are key considerations for expanding patent protection internationally?
Filed through PCT or direct national filings in jurisdictions like the US, China, and Japan to ensure regional protection and manage potential overlaps.
5. How do claim language and patent scope affect commercial strategy?
Broad claims provide wider protection but are more vulnerable during validity challenges; narrow claims are easier to defend but limit market exclusivity.
References
- Taiwan Intellectual Property Office. (2010). Patent Application TW200927136.
- World Intellectual Property Organization. (2022). Patent family analysis and international filings.
- European Patent Office. (2022). Patent search reports and prior art references.
- United States Patent and Trademark Office. (2022). Patent examination guidelines.
- Chinese Patent Office. (2022). Patent landscape reports in pharmaceuticals.
Note: For exact claim language and legal status updates, access the official Taiwan Intellectual Property Office (TIPO) database.
